The risk of antidepressant-induced hyponatremia: A meta-analysis of antidepressant classes and compounds
European Psychiatry · 2024 · 67 (1)
DOI: 10.1192/j.eurpsy.2024.11 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Psychiatry, online erschienen am 26.02.2024. Verfasst von Tim Gheysens und 2 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Antwerp Psychiatric Research Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. Hauptthemen laut MEDLINE: Hyponatremia, Antidepressive Agents. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hyponatremia (hypoNa) is a potentially serious adverse event of antidepressant treatment. Previous research suggests the risk of drug-induced hyponatremia differs between antidepressants. This meta-analysis sought to determine the risk of antidepressant-induced hypoNa, stratified by different compounds and classes.
Methods
A PRISMA-compliant systematic search of Web of Science and PubMed databases was performed from inception until Jan 5, 2023, for original studies reporting incidences or risks of hypoNa in adults using antidepressants. We modelled random-effects meta-analyses to compute overall event rates and odds ratios of any and clinically relevant hypoNa for each compound and class, and ran head-to-head comparisons based on hypoNa event rates. We conducted subgroup analyses for geriatric populations and sodium cut-off value. The study is registered with PROSPERO, CRD42021269801.
Results
We included 39 studies (n = 8,175,111). Exposure to antidepressants was associated with significantly increased odds of hypoNa (k = 7 studies, OR = 3.160 (95%CI 1.911-5.225)). The highest event rates were found for SNRIs (7.44%), SSRIs (5.59%), and TCAs (2.66%); the lowest for mirtazapine (1.02%) and trazodone (0.89%). Compared to SSRIs, SNRIs were significantly more likely (k = 10, OR = 1.292 (1.120 – 1.491), p < 0.001) and mirtazapine significantly less likely (k = 9, OR = 0.607 (0.385 – 0.957), p = 0.032) to be associated with hypoNa.
Conclusion
Our meta-analysis demonstrated that, while no antidepressant can be considered completely risk-free, for hypoNa-prone patients mirtazapine should be considered the treatment of choice and SNRIs should be prescribed more cautiously than SSRIs and TCAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Collaborative Antwerp Psychiatric Research Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
- Scientific Initiative of Neuropsychiatric and Psychopharmacological Studies, University Psychiatric Centre Campus Duffel, Duffel, Belgium.
- Department of Psychiatry, Antwerp University Hospital, Edegem (Antwerp), Belgium.
ORCID-Profile: Tim Gheysens, Filip Van Den Eede, Livia De Picker
Zitieren
APA
Gheysens, T., Van Den Eede, F., & De Picker, L. (2024). The risk of antidepressant-induced hyponatremia: A meta-analysis of antidepressant classes and compounds. European Psychiatry, 67(1). https://doi.org/10.1192/j.eurpsy.2024.11
Vancouver
Gheysens T, Van Den Eede F, De Picker L. The risk of antidepressant-induced hyponatremia: A meta-analysis of antidepressant classes and compounds. European Psychiatry. 2024;67(1). doi:10.1192/j.eurpsy.2024.11
BibTeX
@article{Gheysens2024,
author = {Gheysens, Tim and Van Den Eede, Filip and De Picker, Livia},
title = {The risk of antidepressant-induced hyponatremia: A meta-analysis of antidepressant classes and compounds},
journal = {European Psychiatry},
year = {2024},
volume = {67},
number = {1},
doi = {10.1192/j.eurpsy.2024.11}
}
EUVIMED